Physician profile
Dana Tate
NPI 1598923989
$1,444.30
in general payments reported to CMS, 2019-2025
13 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.67 · 2020: $30.48 · 2021: $133 · 2022: $120 · 2023: $704 · 2024: $194 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $650 · Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $650.02 |
| Food and Beverage | $411.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $826.24 | 2022-2025 | |
| Smith+Nephew, INC. | $149.67 | 2019-2024 | Collagenase Santyl |
| Bone Support INC. | $148.13 | 2024 | Ceramentbone Void Filler, Cerament G |
| Cardiovascular Systems INC. | $67.23 | 2021 | |
| Stryker Corporation | $60.45 | 2025 | N/A |
| Organogenesis INC. | $51.84 | 2021 | |
| Globus Medical, INC. | $30.08 | 2025 | Senza |
| Anika Therapeutics, INC. | $24.25 | 2022 | |
| Integra Lifesciences Corporation | $21.12 | 2023 | Tcc-Ez |
| Paratek Pharmaceuticals, INC. | $18.03 | 2025 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $17.14 | 2023 | Seglentis |
| Cashflow Solutions, LLC | $16.14 | 2023 | Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White |
| Medline Industries LP | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.